HER2-DC1 i.t. combined with anti-HER2 antibodies treatment was able to enhance tumor infiltration of CD8+ T cells compared with HER2-DC1 s.c. combined with anti-HER2 antibodies treatment (figure 3F). Here, ERBB2 is linked to neoplasm.